Among these candidates, based on enzyme-linked immunosorbent assay (ELISA) analysis, Galectin-3-binding protein (Gal-3BP) was verified as one of the potential serological biomarkers for diagnosing HBV-related HCC; moreover, when combined with serum AFP, the diagnostic accuracy of Gal-3BP was enhanced. The gene discussed is LGALS3BP; the disease is hepatocellular carcinoma.